Wolfe Research initiated coverage of Caris Life Sciences (CAI) with an Outperform rating and $32 price target Caris Life Sciences is a high-quality precision oncology company with differentiated therapy selection tests powered by whole-exome and whole transcriptome sequencing, and it delivers “unparalleled” molecular insights to guide personalized cancer treatment, the analyst tells investors in a research note. No other tests on the market provide the depth and breadth of data as WES and WTS, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with a Buy at Citi
- Caris Life Sciences initiated with a Buy at TD Cowen
- Caris Life Sciences initiated with an Outperform at Wolfe Research
- Strong Sales Growth and Strategic Market Expansion Drive Buy Rating for Caris Life Sciences
- Caris Life Sciences initiated with a Buy at Guggenheim